Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in Denmark and Sweden

Nordic Journal of Psychiatry

Volumn 65, Issue 1, 2011, Pages 40-46

  Larsen, John Teilmann ^a,b   Fagerquist, Maria ^c,d   Holdrup, Mette ^c,d   Christensen, Bjarne ^e,f   Sigalin, Catarina ^g,h   Nilsson, Peter M ⁱ  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Janssen Cilag A/S   (Denmark)

^c PFIZER INC   (United States)

^d Box 55 ^*  (Denmark)

^e Aalborg Psykiatriske Sygehus   (Denmark)

^f Treatment Institution at Herstedvester   (Denmark)

^g RYHOV COUNTY HOSPITAL   (Sweden)

^h Janssen Cilag   (Sweden)

ⁱ LUND UNIVERSITY   (Sweden)

Author keywords

Interventions; Metabolic syndrome; Prevalence; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABDOMINAL OBESITY; ADULT; ARTICLE; BLOOD PRESSURE; DENMARK; DIET; EXERCISE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PREVALENCE; PSYCHIATRIST; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SWEDEN; WAIST CIRCUMFERENCE;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CLINICAL COMPETENCE; CROSS-SECTIONAL STUDIES; DENMARK; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; METABOLIC PHENOMENA; METABOLIC SYNDROME X; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEEDS ASSESSMENT; PREVALENCE; SCHIZOPHRENIA; SWEDEN;

EID: 78751519432     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2010.486443     Document Type: Article

References (48)

1. Sarafidis PA, Nilsson PM. The metabolic syndrome: A glance at its history. J Hypertens 2006 24 621-6.
2. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005;28:1769-78.
3. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. Am Heart J 2005; 150:1115-21.
4. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.
5. Hägg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8.
6. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9.
7. Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: A comparative study. J Clin Psychiatry 2007;68:917-23.
8. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Järvelin MR, Laurén LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The northern Finland 1966 Birth Cohort Study. J Clin Psychiatry 2005;66:559-63.
9. Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67:575-83.
10. Cohn T, Prud homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60.
11. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Res 2005;80:19-32.
12. Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M. Concordance of standard and modifi ed NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study. Schizophr Res 2008;99:23-8.
13. Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C; RICAVAStudy Group. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: A crosssectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009 24 431-41.
14. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007;13(7 Suppl):S170-7.
15. Birkenaes AB, Birkeland KI, Friis S, Opjordsmoen S, Andreassen OA. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions. J Clin Psychopharmacol 2009;29:109-16.
16. Hakko H, Komulainen MT, Koponen H, Saari K, Laitinen J, Järvelin MR, et al.; Longitudinal Northern Finland 1966 Birth Cohort Study. Are females at special risk of obesity if they become psychotic? The longitudinal Northern Finland 1966. Birth Cohort Study. Schizophr Res. 2006;84:15-9.
17. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999;156 1686-96.
18. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
19. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-41.
20. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007;24:481-5.
21. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495. 32.
22. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008;371:1085-97.
23. Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 2004;29:1065-70.
24. Holt RIG, Pevelert RC, Byrne CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004;21:515-23.
25. Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obesity Rev 2001;2:73-86.
26. Shiloah E, Witz S, Abramovitch Y, Cohen O, Buchs A, Ramot Y, et al. Effect of acute psychotic stress in nondiabetic patients on beta-cell function and insulin sensitivity. Diabetes Care 2003;26:1462-7.
27. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
28. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001:285 (19).
29. SAS Institute Inc. SAS/STAT User s Guide, Version 8.0. SAS Institute Inc., Cary, NC. 1999.
30. Khunti K, Davies M. Metabolic syndrome. BMJ 2002;331:1153-54.
31. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
32. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5. Epub 2009 Oct 5.
33. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22.
34. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51:492-501.
35. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy, and research challenges. J Clin Psychiatry 2008;69:514-9.
36. APA Practice guideline for the treatment of patients with schizophrenia, 2nd edition. APA; 2004. Accessed at: http://www. psychiatryonline.com/content. aspx?aid-45859
37. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al.; Clozapine and Risperidone Enhancement (CARE) Study Group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;2:472-82.
38. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100.
39. Keck P Jr, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial. Psychopharmacology (Berl) 1988;140:173-84.
40. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry 2005;66: 183-94.
41. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, et al. Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007;21: 357-73.
42. Van Gaal LF. Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol 2006;16 Suppl 3:S142-8.
43. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006;51:502-11.
44. de Leon J, Susce MT, Diaz FJ, Rendon DM, Velsquez DM. Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses. J Clin Psychiatry 2005;66:1447-55.
45. Faulkner G, Taylor A, Munro S, Selby P, Gee C. The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness. Patient Educ Couns. 2007;66:123-6. Epub 2006 Dec
46. Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24.
47. American Diabetes Association. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
48. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24. Epub 2009 Aug 13.